This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Dec;4(12):963-964.

doi: 10.1016/S2213-8587(16)30263-7. Epub 2016 Sep 16.

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Michael A Nauck¹, Juris J Meier²

Affiliations

Affiliations

¹ Division of Diabetology, Medical Department I, St Josef Hospital (Ruhr-University Bochum), Bochum D-44791 Bochum, Germany. Electronic address: michael.nauck@rub.de.
² Division of Diabetology, Medical Department I, St Josef Hospital (Ruhr-University Bochum), Bochum D-44791 Bochum, Germany.

PMID: 27651332
DOI: 10.1016/S2213-8587(16)30263-7

Comment

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Michael A Nauck et al. Lancet Diabetes Endocrinol. 2016 Dec.

. 2016 Dec;4(12):963-964.

doi: 10.1016/S2213-8587(16)30263-7. Epub 2016 Sep 16.

Authors

Michael A Nauck¹, Juris J Meier²

Affiliations

¹ Division of Diabetology, Medical Department I, St Josef Hospital (Ruhr-University Bochum), Bochum D-44791 Bochum, Germany. Electronic address: michael.nauck@rub.de.
² Division of Diabetology, Medical Department I, St Josef Hospital (Ruhr-University Bochum), Bochum D-44791 Bochum, Germany.

PMID: 27651332
DOI: 10.1016/S2213-8587(16)30263-7

Erratum in

Correction to Lancet Diabetes Endocrinol 2016; 4: 963-64.
[No authors listed] [No authors listed] Lancet Diabetes Endocrinol. 2017 Dec;5(12):e8. doi: 10.1016/S2213-8587(17)30370-4. Lancet Diabetes Endocrinol. 2017. PMID: 29173504 No abstract available.

No abstract available

PubMed Disclaimer

Comment on

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Frías JP, et al. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations